Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.47 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.47 |
| ▸ | ATF1 | P18846 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | FOS | P01100 | 2/20 | 0.44 |
| ▸ | JUN | P05412 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24391475 | 0.90 | KDM4E (0.49) | KDM4EBAZ2BBAZ2ANFKB1ATF1 | |
| SCHEMBL29937689 | 0.90 | KDM4E (0.49) | KDM4EBAZ2BBAZ2ANFKB1ATF1 | |
| SCHEMBL17648758 | 0.88 | BAZ2B (0.50) | KDM4EBAZ2BBAZ2ACA12CA1 | |
| SCHEMBL24549949 | 0.84 | KDM4E (0.52) | KDM4ENFKB1ATF1L3MBTL1ALDH1A1 | |
| SCHEMBL31523679 | 0.84 | KDM4E (0.59) | KDM4ENFKB1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL24391491 | 0.84 | KDM4E (0.51) | KDM4ENFKB1ATF1L3MBTL1ALDH1A1 | |
| SCHEMBL29937712 | 0.84 | KDM4E (0.51) | KDM4ENFKB1ATF1L3MBTL1ALDH1A1 | |
| SCHEMBL22717595 | 0.83 | MAPT (0.51) | NFKB1ATF1MAPTGAAMRGPRX4 | |
| SCHEMBL31523620 | 0.82 | KDM4E (0.50) | KDM4ENFKB1ATF1L3MBTL1ALDH1A1 | |
| SCHEMBL3652621 | 0.81 | BAZ2B (0.51) | KDM4EBAZ2BBAZ2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-11-13 | — | — | US | disclosed |
| EP-4536660-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025054488-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | LIEBER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240343740-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-10-17 | — | — | US | disclosed |
| EP-4341255-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117355517-A | Macrocyclic glucagon-like peptide 1 receptor agonists | 伊莱利利公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023238065-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-12-14 | — | — | WO | disclosed |
| CN-115916778-A | Methionine adenosyltransferase inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2022246019-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2022-11-24 | — | — | WO | disclosed |
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2022-07-21 | — | — | US | disclosed |
| EP-3820866-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-112689633-A | For inhibiting Nav1.8 pyridine carboxamide Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343740-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | GLP1R, GCGR, GIPR | KDM4E 2539/4885BAZ2B 2546/4885BAZ2A 2184/4885 |
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN2A | KDM4E 1196/4885BAZ2B 2645/4885BAZ2A 2012/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | KDM4E 2636/4885BAZ2B 4120/4885BAZ2A 3879/4885 |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | SCN8A, SCN1A, SCN2A | KDM4E 1196/4885BAZ2B 2645/4885BAZ2A 2012/4885 |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN1B | KDM4E 2093/4885BAZ2B 3530/4885BAZ2A 3004/4885 |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | WRN, RECQL, BLM | KDM4E 3487/4885BAZ2B 1565/4885BAZ2A 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.